drugset / Trial / NCT06280144
Post-marketing Study of Lyophilized Nasal Spray Live Attenuated Influenza Vaccine
Phase 4
Unknown
6080 enrolled
Changchun BCHT Biotechnology Co.
Hu Bei province Center for Disease control and prevention · collabThe Inner Mongolia Autonomous Region Center for Disease Control and Prevention · collab
RandomizedParallel-groupTriple-blindPrevention
Summary
To evaluate the protective effect 14 days after the live attenuated influenza vaccine; To evaluate the protective effect of vaccination with live attenuated influenza vaccine; To evaluate the safety of freeze-dried nasal spray live attenuated influenza vaccine; To evaluate the detoxification and genetic stability of lyophilized nasal spray vaccine. To evaluate the protective effect of novel coronavirus after 14 days of inoculation with the live attenuated influenza vaccine.
Timeline
- Start
- 2023-09-22
- Primary completion
- 2024-06-30
- Completion
- 2024-10-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Influenza Vaccine, Live, Nasal, Freeze-dried | Vaccine | — | Intranasal |
Indications
No indication recorded.